Drug-by-Drug Side Effect Profiles# Semaglutide (Wegovy/Ozempic)# Semaglutide is the most extensively studied GLP-1 agonist, with GI data from the STEP program (obesity) and SUSTAIN program (T2D)
Foundayo (Orforglipron) Approved in April 2026, Foundayo is a flexible daily oral pill
Dual Hormone Action: Tirzepatide activates GLP-1 and GIP receptors
By limiting oxidative stress, vitamin C reduces inflammation and may prevent the breakdown of collagen and elastin that leads to wrinkles
Kim, S., & Chen, Y
Lang CN, Menza M, Jochem S, Franke G, Perez Feliz S, Brunner M, Koren G, Zehender M, Bugger H, Jung BA, Foell D, Bode C, Odening KE (2016) Electro-mechanical dysfunction in long QT syndrome: role for arrhythmogenic risk prediction and modulation by sex and sex hormones